Sequential Therapy of Atorvastatin Improving Tissue Reperfusion and Clinical Outcomes of ST-elevated Acute Myocardial Infarction Study（The STRAIT Study）
Overview
- Phase
- Not Applicable
- Intervention
- Sequential therapy of atorvastatin
- Conditions
- Acute Myocardial Infarction
- Sponsor
- Zhang Qi, MD
- Enrollment
- 1200
- Locations
- 1
- Primary Endpoint
- Major Adverse Events (MACE) Occourance Rate
- Last Updated
- 9 years ago
Overview
Brief Summary
Statins have been approved to benefit patients underwent percutaneous coronary intervention (PCI). The current study is designed to evaluate the effectiveness and safety of Sequential Therapy of Atorvastatin in patients with ST-elevated myocardial infarction and receive PCI treatment.
Investigators
Zhang Qi, MD
Visa Chief of Department of Cardiology
Shanghai Jiao Tong University School of Medicine
Eligibility Criteria
Inclusion Criteria
- •Sighed informed consent
- •Diagnosised as acute myocardial infarction
- •Time frame less than 12 hours since the occurance of chest pain
- •Aggred to receive sirolimus-eluted coronary stents
- •Patients willing to accepte follow-up
Exclusion Criteria
- •Allegy to statins or with a history against statin therapy
- •Allegy to any products that will be used during PPCI
- •Disagreed to receive PPCI and other related therapy
- •Existing sever liver dysfuntion that statins can not be used according to the guildlines
- •Sever kidney dysfunction (creatinine \>3mg/dl or eGFR\<30ml/min)
- •Sever left ventricular dysfunction (Killip grade 3)
- •Patients are currently taking medicine that may influence the use of statin
- •Patients with a history of alcohol abuse or durg abuse
- •Woman during pregnancy or lactation
- •Patients who has attended other clinical trials
Arms & Interventions
sequential therapy group
80mg atorvastatin before primary PCI (PPCI) followed by 40mg/d for 7 days after PPCI followed by 20mg/d for 1 year
Intervention: Sequential therapy of atorvastatin
Usual Therapy of atorvastatin
20mg/d before and after PPCI for 1 year
Intervention: Sequential therapy of atorvastatin
Outcomes
Primary Outcomes
Major Adverse Events (MACE) Occourance Rate
Time Frame: 30 days
1. Cardiac Death (CD) 2. Non-fatal re-inarction (CK-MB, cTNI or cTNT elevation again and over 3 times higher than up normal limit accompanied with syptoms or EKG indication) 3. revascularization driven by syptoms (CABG or re-PCI)
Secondary Outcomes
- Secondary Endpoints(12 months)